Physician profile
Angelo Tsakopoulos
NPI 1356320774
$4,314.30
in general payments reported to CMS, 2019-2025
30 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $175 · 2021: $533 · 2022: $841 · 2023: $830 · 2024: $913 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.61 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $556.61 | 2021-2025 | |
| Lilly USA, LLC | $551.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $522.37 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $486.35 | 2021-2025 | Viberzi, Linzess, Vraylar |
| Pfizer INC. | $409.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.89 | 2020-2025 | Jardiance |
| Currax Pharmaceuticals LLC | $235.77 | 2021-2025 | Contrave, Onzetra Xsail, Nexletol |
| Novartis Pharmaceuticals Corporation | $155.95 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $139.87 | 2022-2025 | Farxiga, Airsupra |
| Radius Health, INC. | $138.40 | 2024-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.09 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $97.40 | 2021-2022 | |
| Exact Sciences Corporation | $93.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.37 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $57.77 | 2024 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $54.31 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $46.55 | 2021-2024 | Eliquis |
| Abbott Laboratories | $43.17 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $40.39 | 2023-2024 | Shingrix, Arexvy |
| Amgen INC. | $34.18 | 2025 | Evenity |
| Mylan Specialty L.P. | $32.18 | 2023 | Yupelri |
| Dexcom, INC. | $23.65 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $17.18 | 2021 | |
| Sumitomo Pharma America, INC. | $17.04 | 2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $15.70 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.79 | 2022 | |
| Allergan, INC. | $14.16 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.67 | 2023 | Quviviq |
| Genentech USA, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Tsakopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.